MDT

95.08

-1.43%↓

VEEV

287.03

-0.52%↓

139.3

+0.04%↑

HQY

92.74

-2.71%↓

TLRY

1.68

+3.7%↑

MDT

95.08

-1.43%↓

VEEV

287.03

-0.52%↓

139.3

+0.04%↑

HQY

92.74

-2.71%↓

TLRY

1.68

+3.7%↑

MDT

95.08

-1.43%↓

VEEV

287.03

-0.52%↓

139.3

+0.04%↑

HQY

92.74

-2.71%↓

TLRY

1.68

+3.7%↑

MDT

95.08

-1.43%↓

VEEV

287.03

-0.52%↓

139.3

+0.04%↑

HQY

92.74

-2.71%↓

TLRY

1.68

+3.7%↑

MDT

95.08

-1.43%↓

VEEV

287.03

-0.52%↓

139.3

+0.04%↑

HQY

92.74

-2.71%↓

TLRY

1.68

+3.7%↑

Home・Lista de Ações・Cogent Biosciences Inc

Cogent Biosciences Inc

Abrir

16.37 6.09

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

15.2

Máximo

16.48

Indicadores-chave
By Trading Economics
Rendimento	-1.5M -74M
Margem de lucro	-1,582.642
Funcionários	205
EBITDA	1.7M -72M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+31.48% upside

Dividendos
By Dow Jones
Próximos Ganhos	10 de nov. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	583M 2.3B
Abertura anterior	10.28
Fecho anterior	16.37

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

4.88 / 5.87 Suporte e Resistência

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de out. de 2025, 22:33 UTC

Ganhos

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 de out. de 2025, 22:21 UTC

Grandes Movimentos do Mercado

Dentsply Sirona Shares Rise After SEC Probe Ends

14 de out. de 2025, 19:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 de out. de 2025, 17:56 UTC

Grandes Movimentos do Mercado

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 de out. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 de out. de 2025, 22:12 UTC

Conversa de Mercado

Ganhos

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 de out. de 2025, 21:40 UTC

Ganhos

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 de out. de 2025, 21:39 UTC

Ganhos

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 de out. de 2025, 21:38 UTC

Ganhos

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 de out. de 2025, 21:06 UTC

Ganhos

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 de out. de 2025, 20:50 UTC

Conversa de Mercado

Ganhos

Financial Services Roundup: Market Talk

14 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

14 de out. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

14 de out. de 2025, 20:50 UTC

Conversa de Mercado

Ganhos

Health Care Roundup: Market Talk

14 de out. de 2025, 20:13 UTC

Ganhos

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 de out. de 2025, 20:01 UTC

Ganhos

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 de out. de 2025, 19:21 UTC

Conversa de Mercado

Ganhos

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 de out. de 2025, 19:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 de out. de 2025, 19:08 UTC

Conversa de Mercado

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 de out. de 2025, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 de out. de 2025, 18:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 de out. de 2025, 18:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 de out. de 2025, 18:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 de out. de 2025, 18:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 de out. de 2025, 18:46 UTC

Ganhos

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 de out. de 2025, 18:04 UTC

Ganhos

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 de out. de 2025, 18:01 UTC

Conversa de Mercado

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 de out. de 2025, 17:54 UTC

Ganhos

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 de out. de 2025, 17:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de out. de 2025, 17:50 UTC

Conversa de Mercado

Lower Dollar Provides Some Strength in Grains -- Market Talk

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

31.48% parte superior

Previsão para 12 meses

Média 21.3 USD 31.48%

Máximo 30 USD

Mínimo 11 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

4.88 / 5.87Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.